LUCIRA™ HEALTH Hires Tony Allen as Chief Operations Officer
September 20 2021 - 4:01PM
Lucira Health, Inc. (“Lucira Health” or “Lucira”) (NASDAQ: LHDX), a
medical technology company focused on the development and
commercialization of transformative and innovative infectious
disease test kits, today announced operations expert Tony Allen has
joined the company as Chief Operations Officer.
“Tony has a stellar track record in operations management. We’re
delighted that he’s bringing his experience, skill set, and high
energy level to Lucira as we continue expanding production and the
capabilities of our unique test for COVID-19 and then other
pathogens,” said CEO Erik Engelson.
Allen comes to Lucira with 25 years’ experience in operations
and management. Most recently, he was Vice President and Head of
Global Internal Manufacturing at Ortho-Clinical Diagnostics, Inc.,
an in vitro diagnostics company. At Alcon, Inc., an eye care device
company, he was Global Senior Project Management Office Head, and
was Vice President of Operations at Accriva Diagnostics Holdings,
Inc., a medical equipment and supplies manufacturing company in San
Diego. He also held Senior VP positions in operations at DJO
Global, Inc., a developer of medical devices, and has nine years of
management experience in operations with NEC Computers
International, an information technology and electronics company.
Allen holds an Executive MBA from Aberdeen University.
“Lucira is a ‘right place - right time - right tech’ healthcare
company,” said Allen. “I’m looking forward to collaborating with
the team to work towards increasing production, streamlining
operations, and increasing product availability worldwide.”
About Lucira Health
Lucira is a medical technology company focused on the
development and commercialization of transformative and innovative
infectious disease test kits. Lucira’s testing platform produces
lab quality molecular testing in a single-use, consumer-friendly,
palm-size test kit powered by two AA batteries. Lucira designed its
test kits to provide accurate, reliable, and on-the-spot molecular
test results anywhere and at any time. The LUCIRA™ CHECK IT
COVID-19 Test Kit (OTC) and LUCIRA™ COVID-19 All-In-One Test Kit
(Rx) are designed to provide a clinically relevant COVID-19 result
within 30 minutes from sample collection. For more information,
visit www.lucirahealth.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995. Such forward-looking statements include statements
regarding, among other things, Lucira’s continued development and
commercialization of its transformative and innovative infectious
disease test kits and ability to increase sales. Because such
statements are subject to risks and uncertainties, actual results
may differ materially from those expressed or implied by such
forward-looking statements. Words such as “can” “plans,” “will,”
“may,” “anticipates,” “expects,” “potential” and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon Lucira’s current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results could differ materially
from those anticipated in such forward-looking statements as a
result of various risks and uncertainties, including our ability to
increase production, streamline operations and increase product
availability, the success of our test platform with COVID-19, the
impact to our business of the ongoing COVID-19 pandemic; any impact
on our ability to market our products; demand for our products due
to deferral of procedures using our products or disruption in our
supply chain; our ability to achieve or sustain profitability; our
ability to gain market acceptance for our products and to
accurately forecast and meet customer demand; our ability to
compete successfully; our ability to enhance our product offerings;
development and manufacturing problems; capacity constraints or
delays in production of our products; maintenance of coverage and
adequate reimbursement for procedures using our products; and
product defects or failures. These and other risks and
uncertainties are described more fully in the “Risk Factors”
section and elsewhere in our filings with the Securities and
Exchange Commission and available
at www.sec.gov, including in our most recent
Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Any
forward-looking statements that we make in this announcement speak
only as of the date of this press release, and Lucira assumes no
obligation to update forward-looking statements whether as a result
of new information, future events or otherwise after the date of
this press release, except as required under applicable law.
Media ContactKevin
Knightmedia@lucirahealth.com206-451-4823
Investor ContactGreg
ChodaczekInvestorrelations@lucirahealth.com347-620-7010
Lucira Health (NASDAQ:LHDX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lucira Health (NASDAQ:LHDX)
Historical Stock Chart
From Sep 2023 to Sep 2024